Redondo, AndresRamos Vazquez, ManuelManso, LuisGil Gil, Miguel JGarau Llinas, IsabelGarcia-Garre, ElisaRodriguez, Cesar AIgnacio Chacon, JoseLopez-Vivanco, Guillermo2024-09-062024-09-062018Redondo A, Ramos Vazquez M, Manso L, Gil Gil MJ, Garau Llinas I, Garcia-Garre E, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational LORENA study. OncoTargets Ther. 2018;11:5845-52.1178-6930http://hdl.handle.net/20.500.13003/17168https://hdl.handle.net/20.500.12105/22624Background: Randomized controlled trials of the first-line combination of bevacizumab and chemotherapy in patients with metastatic breast cancer (MBC) have shown improvements in tumor response and progression-free survival (PFS). Objective: The aim of this ambispective, observational study (LORENA) was to describe the clinical characteristics of long-term responders to bevacizumab-based therapy. Patients and methods: This study consisted of a retrospective and a prospective phase. During the retrospective phase, patients with HER2-negative MBC who were treated with bevacizumab-based first-line therapy were included. During the prospective phase, patients with PFS of >= 12 months were treated according to routine clinical practice procedures. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method. Univariate and multivariate analyses of prognostic factors were performed. Results: In total, 148 women were included (median age: 50 years; range: 29.-411 years). The mean duration o f exposure to bevacizumab was 18 months. The majority of patients experienced objective response (complete: 23%; partial: 57%). Median PFS was 22.7 months and median OS was 58.2 months. In multivariate analyses, patients receiving maintenance hormonal therapy (MHT) had longer PFS (P=0.002; hazard ratio [HR] =1.8) and OS (P=0.009; HR=2.0), while patients not previously treated with taxanes had longer OS (P<0.0001; HR =3.3). No unexpected adverse events were observed. Conclusion: The results of this study suggest, that among long-term responders, first-line bevacizumab-based therapy is more effective in patients who had not been previously treated with taxanes, and that MHT provides additional therapeutic benefits by extending PFS and OS.engBevacizumabMetastatic breast cancerReal-worldMaintenance hormonal therapyTaxaneresearch articleAttribution-NonCommercial 3.0 Unported30271167115745-585210.2147/OTT.S170303Oncotargets and Therapyopen access2-s2.0-85057966900445036600001L625289904